Ranexa (previously Latixa)
- Prescription status not stated
- Heart, blood pressure and circulation
- Active substance
- Ranolazine
- Made by
- Menarini International Operations Luxembourg S.A. (MIOL)
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Ranexa is indicated as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line anti-anginal therapies (such as beta-blockers and / or calcium antagonists).
From the official label · 2026-09-30 · European Medicines Agency
How it works
From the US prescribing label for the same active substance (Ranolazine). It describes the substance, not this exact product.
The mechanism of action of ranolazine’s antianginal effects has not been determined.
Ranolazine has anti-ischemic and antianginal effects that do not depend upon reductions in heart rate or blood pressure.
Ranolazine is extensively metabolized in the gut and liver and its absorption is highly variable.
Following a single oral dose of ranolazine solution, approximately 75% of the dose is excreted in urine and 25% in feces.
The pharmacokinetics of ranolazine is unaffected by age, gender, or food.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-08-19
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
SpainNo exact match for this strength and form
FranceNo exact match for this strength and form
CanadaNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
SwitzerlandNo exact match for this strength and form
Details
| Made by | Menarini International Operations Luxembourg S.A. (MIOL) |
|---|---|
| Active substance | Ranolazine |
| Used in | Heart, blood pressure and circulation |
| Classification | C01EB18 · Heart, blood pressure and circulation |
| Authorised on | 2008-07-08 |
| Last updated by the regulator | 2024-04-10 |
| EMA product number | EMEA/H/C/000805 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).